Faculty Bibliography

INTRODUCTION/BACKGROUND:The subset of patients admitted to the intensive care unit (ICU) following total joint arthroplasty (TJA) has yet to be studied in detail. Specifically, there is little data on the effects of vasopressor administration in patients who require critical care after TJA. We sought to characterize patient outcomes and mortality by vasopressor administration in the ICU following primary TJA. METHODS:We retrospectively reviewed 187 patients who required admission to the ICU within 14 days following primary, unilateral TJA from 2012 to 2024, out of 47,083 patients who underwent TJA during this time (0.40%). Exclusion criteria included TJA for trauma, acute fracture, and revision or conversion TJA. Patients were classified by whether they received any vasopressor (i.e., norepinephrine, phenylephrine, or vasopressin) medication at any point during their ICU stay. Limited intraoperative use of vasopressor did not qualify. Demographic and surgical data were collected and compared. Primary outcomes included complications, revisions/reoperations. RESULTS:Of the 187 patients requiring ICU admission following primary TJA, 20 received vasopressors during their stay. No significant demographic differences were found between cohorts. Hypotension (26%) was the most common indication for ICU admission. Vasopressor use was not associated with a significant increase in 30-day or one-year mortality (5.0 vs. 0.6%, P=0.07; 5.0 vs. 1.2%, P=0.20, respectively), but was associated with a significant increase in revisions/reoperations 25.0 vs 6.0%, P=0.005). No significant differences were observed for 90-day VTE events (P=0.62). Dislocations were significantly more common in patients who received vasopressors (14.3 vs. 1.0%, P=0.047). CONCLUSION/CONCLUSIONS:Patients who received vasopressors in the ICU following TJA had significantly higher rates of revisions, reoperations, and dislocation. There were no differences in mortality rates or VTE rates between groups. Further investigation is required to better characterize outcomes following vasopressor requirement in the total joint arthroplasty population.

BACKGROUND:10 years after changing our institution's total hip arthroplasty (THA) preoperative antibiotic prophylactic protocol by adding gram-negative (GN) coverage, this study aimed to assess the impact of adding GN specific coverage (GNSC) prior to THA on periprosthetic joint infection (PJI) rates. METHODS:This was a retrospective case-control study of 14,598 patients who underwent primary, elective THA between July 2012 and January 2022, with minimum 1-year follow-up. All patients were under perioperative antibiotic protocol that included GNSC with either weight-based gentamicin or aztreonam (+GNSC) and were compared to a historical control group of patients for which the antibiotic prophylactic protocol did not include GNSC (-GNSC). PJI and nephrotoxicity rates, as well as the severity of nephrotoxicity according to the RIFLE criteria, were compared between the study populations and 4122 controls. RESULTS: = 0.567), which are the two more severe forms of nephrotoxicity, were comparable between the groups. CONCLUSIONS:The addition of gentamicin or aztreonam prior to THA reduces the incidence of GN-related PJIs. Increased nephrotoxicity rates were limited to the mildest form, usually associated with reversibility and favourable outcomes.

PURPOSE/OBJECTIVE:mapping technique for imaging of body parts containing metal hardware, based on magnitude images acquired with turbo spin echo (TSE) pulse sequences. THEORY AND METHODS/METHODS:values were validated against gradient-recalled and spin echo dual angle methods, as well as a vendor-provided TurboFLASH-based mapping sequence, in gel phantoms and human subjects without and with metal implants. RESULTS:shimming. CONCLUSION/CONCLUSIONS:values in regions near metal hardware, overcoming susceptibility-related and narrow-range limitations of standard mapping techniques.

INTRODUCTION/BACKGROUND:To our knowledge, outcomes of patients undergoing staged, bilateral total hip arthroplasty (THA) via dissimilar surgical approaches have not yet been investigated. This study examined demographics, implant selection, technology utilization, and component positioning between hips in patients who underwent one THA via posterior and one via direct anterior approach and secondarily evaluated patient-reported outcomes. METHODS:There were 36 patients (72 hips) who underwent staged, bilateral, primary, elective THAs via different approaches from January 2012 to December 2023. Patient demographics, intraoperative technology utilization, implants used, and pre- and postoperative Hip Dysfunction and Osteoarthritis Outcome Scores for Joint Replacement (HOOS-JR) scores were recorded. The hip center of rotation, acetabular height and anteversion, and metaphyseal canal fill were measured on postoperative radiographs. Femoral stem coronal and sagittal plane angulation following both approaches were also compared on postoperative radiographs. RESULTS:There were 15 (41.7%) patients who underwent posterior THA first. The mean time between operations was five years (range, 0.93 to 10.2). Intraoperative technology utilization was more common for the anterior THA (P = 0.002). There were no significant differences in hip center of rotation (P = 0.292), acetabular anteversion (P = 0.428), or acetabular height (P = 0.935) between patients' anterior and posterior approach THAs. The proportion of patients who had posterior stem angulation was significantly greater following anterior THA; neutral stem angulation was seen more frequently following posterior THA (P = 0.005). Lipped liners (P < 0.001), high offset femoral stems (P = 0.007), and dual or triple-taper stems (P < 0.001) were more commonly utilized in posterior THAs. For patients who had pre- and postoperative HOOS-JR for each hip, there was no significant difference in postoperative score improvement between anterior and posterior THAs (P = 0.697), with a mean follow-up time of 2.4 years (range, 0.3 to 9.28) for posterior and 6.1 years (range, 2.8 to 10.3) for anterior THAs (P = 0.249). CONCLUSIONS:Patients undergoing staged, bilateral THAs via different surgical approaches exhibit radiographic characteristics likely attributable to technical challenges for each approach. However, these differences related to approach do not seem to impact short-term clinical and patient-reported outcomes.

BACKGROUND:Corticosteroid injections following total hip arthroplasty (THA) are commonly utilized to address soft-tissue pathology such as bursitis and tendinitis. The THA surgical approaches differ in the extent of muscle and soft-tissue dissection. The aim of this study was to compare the impact of surgical approach on postoperative corticosteroid injection requirements when controlling for multiple covariates. A secondary aim was to identify risk factors associated with the various injection types. METHODS:This was a propensity-matched retrospective study of 10,907 THA patients from June 2016 to December 2022 at a single, urban, academic health center. Patients were stratified into cohorts based on surgical approach: anterior (n = 4,287) and posterior (n = 6,620), then propensity-matched 1:1 with nearest-neighbor matching to form two cohorts of 4,287 patients. Baseline characteristics and corticosteroid injection data for soft-tissue pathology were obtained and analyzed. Chi-square and multivariate logistic regression analyses were used to assess the impact of patient and surgical factors on receiving postoperative steroid injections. RESULTS:A posterior approach conferred increased risk of postoperative injections (aOR [adjusted odds ratio] 1.242, P = 0.001) after controlling for multiple covariates. The posterior approach also had higher total rates of greater trochanter (GT) bursitis injections postoperatively compared to the anterior group (11.5 versus 7.3%, P < 0.001). Both surgical approaches demonstrated comparable rates of iliopsoas bursitis injections (P = 0.39), gluteus medius tendinosis injections (P = 0.09), and lateral femoral cutaneous nerve injections (P = 0.27). The strongest predictor of postoperative injections was a history of preoperative injection (aOR 3.772, P < 0.001). CONCLUSION/CONCLUSIONS:Posterior approach, women, and history of preoperative corticosteroid injection were identified as the strongest risk factors for postoperative GT bursitis injection or postoperative soft-tissue injection. These factors should be considered when counseling patients on expected postoperative outcomes and the likelihood of corticosteroid injections following THA.

BACKGROUND:With the increased rates of revision total hip (rTHA) and total knee arthroplasty (rTKA), the financial burden of these procedures is at risk of straining the healthcare system. Our study sought to create a model to evaluate the cost-effectiveness of rTKA and rTHA performed by high-volume (HV) and low-volume (LV) surgeons. METHODS:percentile in annual volume were classified as HV surgeons and the remainder were classified as LV surgeons. Previously published cost estimates were utilised for operative time, hospital length of stay (LOS), discharge disposition, 90-day readmission, and 1-year re-revision. RESULTS: < 0.001). Both groups had equivalent discharge disposition, 90-day readmission, and 1-year re-revision. HV surgeons had lower estimated mean costs for rTHA ($22,027.81 vs. $24,617.39) and rTKA ($20,343.23 vs. $18,554.67). CONCLUSIONS:HV surgeons have a lower estimated mean cost for both rTHA and rTKA. Healthcare systems may benefit from having rTHA and rTKA procedures performed by HV surgeons who are able to perform these revision procedures for a lower cost without negatively impacting patient outcomes.

INTRODUCTION/BACKGROUND:Technology is increasingly incorporated into unicompartmental knee arthroplasty (UKA) through computer-assisted navigation (N-UKA) and robot-assisted surgery (R-UKA) to improve alignment, implant positioning, and gap balancing. Whether intraoperative technology helps achieve the minimal clinically important difference (MCID) in patient-reported outcomes (PROMs) compared to conventional UKA (C-UKA) remains unclear. This systematic review aimed to assess whether differences in PROMs between C-UKA and technology-assisted UKA reached MCID values. MATERIALS AND METHODS/METHODS:PubMed/MEDLINE/Cochrane Library were reviewed for studies comparing PROMs between primary C-UKA (control group) and N-UKA or R-UKA. Delta improvements were compared to established MCID values. Additional radiographic and clinical differences were assessed. The review yielded four (N=328) N-UKA and seven (N=526) R-UKA studies with C-UKA cohorts as controls. RESULTS:Differences in preoperative and postoperative PROMs were reported as statistically significant in three of four studies (75%) comparing N-UKA and C-UKA; however, none of the studies reported values that reached the MCID. Differences in preoperative and postoperative PROMs were reported as statistically significant in four of seven studies (57.1%) comparing R-UKA and C-UKA; however, only three of the studies (42.9%) reported values that reached the MCID. Improved radiographic outcomes for N-UKA and R-UKA were reported in 75% and 57.1% of studies, respectively. Only one study reported improved revision rates with R-UKA compared to C-UKA. CONCLUSION/CONCLUSIONS:Though studies may report better improvements in PROMs in N-UKA and R-UKA compared to C-UKA, these often may not achieve clinical significance. Future studies should present outcome differences in the context of validated MCID as well as other metrics such as revision rates and radiographic outliers as the impetus for technology-assisted UKA.

BACKGROUND:Traveling fellowships, such as the Hip Society Rothman-Ranawat fellowship, offer orthopaedic surgeons the opportunity to enhance their skills, conduct research, and gain mentorship at top orthopaedic centers. This study aimed to assess the impact of the Hip Society Rothman-Ranawat traveling fellowship on an adult reconstruction surgeon's career. METHODS:A non-incentivized online survey was distributed to the 40 past recipients of the Hip Society Rothman-Ranawat traveling fellowship spanning from 2013 to 2023. The survey comprised short-answer questions and multiple-choice questions to evaluate the impact of the traveling fellowship. Surgeon publication counts and h-indexes were extracted from the Scopus database before the fellowship and at intervals of three years, five years, and the present post fellowship. Quantitative metrics were adjusted based on the time elapsed since the surgeon completed the fellowship and compared using paired-sample t-tests. RESULTS:This study had a 95% response rate (n = 38). Following the completion of the fellowship, we observed an increase in publication count and h-index at various intervals compared to the time before the fellowship. The mean annual percentage increase in publication count was 25.6% at the 3-year mark, 37.6% at the 5-year mark, and 29.4% at the present time, all relative to the publication count before the fellowship. Similarly, the mean annual percentage increase in the h-index was 9.7% at the 3-year mark, 9.6% at the 5-year mark, and 4.1% at the present time, all compared to the h-index before the fellowship. Qualitative measures showed previous fellows endorsed that the fellowship positively changed their clinical practice (84% agreement), expanded their network (97% agreement), increased research productivity (82% agreement), and improved surgical technique (74% agreement). CONCLUSION/CONCLUSIONS:Responses from past Hip Society Rothman-Ranawat traveling fellows suggest that participating in the fellowship positively influenced their career trajectories.

BACKGROUND:Obesity and diabetes mellitus (DM) pose challenges for patients undergoing total knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as agents for weight and DM management, but they affect multiple organ systems. Outcomes, trends, and demographics for perioperative GLP-1RA use in patients with TKA are not well understood. METHODS:A retrospective review of 13,751 primary, elective TKAs with at least 90 days of follow-up at an urban academic health system between 2012 and 2023 identified 865 patients who had perioperative GLP-1RA use. A 10:1 propensity score match based on sex, age, smoking status, American Society of Anesthesiologists classification, and body mass index created a control cohort of 8,650 TKAs with no GLP-1RA use. RESULTS:The use of GLP-1RAs varied significantly by race, Medicaid insurance, Charlson Comorbidity Index, and presence of DM. Black and Latino patients and those covered by Medicaid were significantly less likely to receive GLP-1RAs. The GLP-1RA group had significantly shorter length of stay (2.1 versus 2.5 days, P < 0.001) and a higher rate of home discharge (91.7 versus 84.2%, P < 0.001). The GLP-1RA users had significantly higher rates of 90-day emergency department visits (5.9 versus 4.0%, P = 0.008), but no differences in 90-day readmissions (4.3 versus 3.6%, P = 0.168) or 2-year revision (2.3 versus 2.6%, P = 0.362) compared to matched controls. The GLP-1RA patients had significantly lower all-cause revision rates at the last follow-up (2.7 versus 3.9%, P = 0.034), but there was no significant difference in Kaplan-Meier implant survival (P = 0.311). Before TKA, GLP-1RA patients had an average decrease in body mass index of 0.4, compared to an average increase of 1.2 for matched controls. CONCLUSIONS:Our results demonstrate that the use of GLP-1RAs is significantly lower for minority patients and those covered by Medicaid. Patients using GLP-1RAs have noninferior clinical outcomes with the potential for weight loss leading up to TKA. LEVEL OF EVIDENCE/METHODS:III.

BACKGROUND:Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase fluid retention and the risk of heart failure (HF). Type 2 diabetes mellitus (T2DM) is known to increase the risk of cardiac disease, including HF. As part of a modern multimodal pain protocol, NSAIDs are commonly used in total knee arthroplasty (TKA), but the risk of NSAID use in TKA for T2DM patients is not well understood. The purpose of this study was to compare rates of new-onset HF following TKA in Type 2 diabetics with varying NSAID use. METHODS:We reviewed 3,906 patients who underwent primary TKA from 2015 to 2023 at a single academic institution. Data collected included demographics, preoperative diagnosis of T2DM, postoperative development of new-onset HF, NSAIDs taken perioperatively, and aspirin use for deep vein thrombosis (DVT) prophylaxis. Propensity matching was conducted to control for age, American Society of Anesthesiologists (ASA) Score, and aspirin use. Rates of postoperative HF within T2DM patients who took meloxicam versus celecoxib were compared using Chi-square analyses. RESULTS:Among patients who took meloxicam or celecoxib perioperatively, a preoperative diagnosis of T2DM was disproportionately associated with postoperative HF (P = 0.006). When comparing peri-TKA use of meloxicam versus celecoxib in T2DM patients, the use of celecoxib was disproportionately associated with the development of postoperative HF (2.2% [meloxicam], 4.8% [celecoxib], P = 0.002). CONCLUSIONS:We found patients who had T2DM developed postoperative HF at higher rates compared to non-diabetics following peri-TKA NSAID use and that T2DM patients developed new-onset HF at higher rates when utilizing celecoxib than meloxicam in the peri-TKA period. Along with the many other factors that contribute to an orthopaedic surgeon's decision on which NSAID to use postoperatively, we advocate for consideration of the risk of new-onset HF in T2DM patients when prescribing meloxicam and celecoxib in the post-TKA period.